Rocket Lab's Commercial Backlog Grows as Neutron Timeline and NASA Decision Loom

Rocket Lab shares sit 54% below their 52-week high as Neutron's first flight slips and NASA's $30 billion lunar launch awards pass it by.

Rocket Lab finds itself at a crossroads that neatly captures the twin forces shaping the commercial space industry: dependable niche demand on one side, and the gravitational pull of government megaprojects on the other. The company's Electron rocket continues to win repeat business, yet its next-generation Neutron vehicle and a pending NASA procurement decision will do more to set the stock's direction than any single contract signed this year.

The shares finished Friday at €60.90, roughly 54% below their 52-week high of €133.80. Over the past seven days alone, the stock has shed 7.3%, a pullback that reflects mounting operational hurdles rather than idle market noise.

NASA's $30 Billion Lunar Ambition Sets the Stakes

According to a Bloomberg report, NASA is preparing bundled launch contracts tied to its planned lunar base program, with a total volume of $30 billion. Rocket Lab was not named among the selected providers in that report. For a company still best known for small-satellite launches, the omission matters: these awards would lock in years of capacity utilization and determine the pecking order for future exploration missions.

The strategic question is whether Rocket Lab can grow profitably without a seat at the table for the largest government launch programs. As space agencies concentrate spending on lunar exploration, a growing share of operational activity shifts toward private-sector constellations. Investors must weigh whether recurring commercial missions alone can carry the heavy development and infrastructure costs — or whether exclusion from government budgets becomes a lasting growth ceiling.

Neutron's First Flight Slips Further Out

The Neutron rocket remains Rocket Lab's central bet, designed to lift the company out of the small-payload segment and into the more lucrative medium-weight class, where it would challenge SpaceX's Falcon 9. That front is where the warning signs are multiplying.

After cracks in the first stage forced a redesign of the tank, CEO Peter Beck acknowledged that a maiden flight before year-end is looking increasingly unlikely. The company is targeting delivery to the launch pad in the fourth quarter of 2026, but delays in space projects carry outsized consequences. Every lost month adds financial strain — and the numbers already tell a stark story. Free cash flow came in at minus $110.12 million in the second quarter of 2026, underscoring the sheer cost of simultaneous development programs.

For the third quarter, Rocket Lab has guided toward revenue of $250 million to $265 million, alongside an expected adjusted EBITDA loss of between $17 million and $23 million. Competing in space, in other words, demands deep pockets.

Wall Street Trims Targets but Keeps the Faith

Analysts are adjusting to the new reality. Barclays initiated coverage on October 8 with an Overweight rating and an $85 price target. TD Cowen's Gautam Khanna reaffirmed his buy recommendation on October 9 but slashed his target sharply, from $120 to $90. The move signals that the growth story itself isn't in doubt — the prior valuation simply ran too far ahead of the fundamentals.

Adding to the risk profile is Rocket Lab's agreed acquisition of Iridium for roughly $8 billion, a deal for which $1.94 billion has already been raised through share sales. The transaction isn't expected to close until mid-2027 and hinges on regulatory approvals. It ties up enormous resources at a moment when the core operating business should command full attention.

Electron's Order Book Provides the Counterweight

Against those pressures, the established Electron business keeps delivering. Roughly a week ago, Rocket Lab secured a multi-year agreement with Synspective covering 20 additional Electron missions — the largest commercial contract yet for the Electron rocket. Flights are to be carried out in annual tranches from 2028 through 2031.

With the new order, total contracted launches for Synspective rise to 47 Electron missions. A backlog locked in that far into the future demonstrates durable demand in Earth observation and satellite networks, and it proves Rocket Lab can deliver reliably in a segment where customers depend on firmly scheduled launch windows. If the company keeps expanding this commercial core, its reliance on any single government tender diminishes noticeably.

Chart Levels and the Catalysts Ahead

Technically, the picture hinges on whether the stock can reclaim its 200-day moving average of €71.15. Until it does so convincingly, a wait-and-see mood is likely to prevail. A slide below recent interim lows would reinforce the bearish case and point to further downside adjustment; a return above the moving average could lay the groundwork for a re-rating.

The next concrete catalyst is NASA's official announcement of contract awards under the lunar base program. Only when the selected partners are formally named will there be clarity on what role — if any — Rocket Lab will play in long-term U.S. space plans. At the same time, the market will be watching closely for additional large commercial launch orders in the coming months, which would help secure capacity utilization beyond 2028.

For now, Rocket Lab sits at a critical junction. Delays on Neutron, continued cash burn, and an ambitious acquisition have raised the stock's risk premium — and the burden of proof rests squarely with management.